BioLite Receives $230,000 Milestone Payment from AiBtl in Botanical Drug Collaboration

BioLite, Inc., a subsidiary of ABVC BioPharma, has received a $230,000 milestone payment from AiBtl BioPharma under their strategic licensing agreement for botanical-derived drug candidates ABV-1504 and ABV-1505, targeting Major Depressive Disorder and Attention-Deficit/Hyperactivity Disorder. This payment brings the cumulative cash received by BioLite to $230,000, while ABVC, as majority owner and co-licensor, has separately collected $350,000 to date. The licensing agreement positions both entities to receive up to $13,420,000 in future cash payments contingent on milestone achievements, alongside equity consideration comprising 46,000,000 common shares issued by AiBtl.

The collaboration taps into significant market opportunities, with the anxiety and depression treatment market valued at approximately $15.4 billion in 2024 and projected to reach $19.3 billion by 2030. Similarly, the ADHD therapeutics market was valued at $14.3 billion in 2023 and is expected to grow to $18.6 billion by 2030. These markets reflect substantial unmet medical needs, as depression affects over 380 million people globally according to the World Health Organization, while the Centers for Disease Control and Prevention reports ADHD affects 9.8% of U.S. children.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that the milestone payment underscores progress in the collaboration with AiBtl, highlighting the potential of botanical-based treatments to address global health challenges. The partnership combines cash inflows, equity stakes, and market opportunities that could total approximately $667 million in potential value based on internal valuations, positioning ABVC to strengthen its balance sheet and pursue leadership in botanical-derived psychiatric therapies. This strategic move aligns with growing interest in alternative treatments for CNS disorders, leveraging botanical derivatives to expand therapeutic options amid rising prevalence of mental health conditions worldwide.